Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dual-targeting antibody targeting scf and galectin-1 and use thereof

一种半乳糖凝集素、干细胞因子的技术，应用在抗细胞因子/淋巴因子/干扰素免疫球蛋白、抗体、抗动物/人类的免疫球蛋白等方向，能够解决视力损害、失明等问题，达到增加透过性、预防或治疗血管生成相关疾病的效果

Active Publication Date: 2020-06-16
NOVELTY NOBILITY INC
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Especially, in the above-mentioned diseases, neovascularization in the cornea suppresses the transparency of the eyeball to cause visual impairment, and neovascularization in the retina produces blood oozing due to abnormal blood vessel formation and is caused by deformation of retinal cells blindness

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual-targeting antibody targeting scf and galectin-1 and use thereof
  • Dual-targeting antibody targeting scf and galectin-1 and use thereof
  • Dual-targeting antibody targeting scf and galectin-1 and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0040] Hereinafter, the present invention will be described in detail.

[0041] In the present invention, terms not otherwise defined have meanings commonly used in the field to which the present invention pertains.

[0042] The present inventors took the lead in preparing a dual-targeting antibody that inhibits the formation of new blood vessels in angiogenesis-related diseases to effectively prevent or treat the above diseases.

[0043] The dual targeting antibodies described above are capable of inhibiting or amplifying two signals at the same time and are thus more effective than inhibiting / amplifying one signal and have the potential to be administered at low doses compared to the case of treating each signal with individual signal inhibitors And it can suppress / amplify two signals at the same time and space.

[0044] In the present invention, dual targeting antibodies may be "polyclonal" or "monoclonal" antibodies, but are more preferably monoclonal antibodies. A monoc...

Embodiment 1

[0109] Example 1. Preparation of dual targeting antibody-producing cell lines targeting stem cell factor and galectin-1

[0110] 1-1. Immunization of mice

[0111] 50 μg of recombinant stem cell factor (SCF, Stem Cell Factor) protein (cat#7466-SC) purchased from R&D systems was mixed with an equal volume of complete Freund's Adjuvant (Freund's Adjuvant) (sigma company, U.S.) to prepare an emulsion ( based on one mouse). The emulsion was injected intraperitoneally into four 7-week-old female humanized NSG mice injected with human CD34+ cells. Thereafter, 50 µg of antigen was injected into each mouse in a total volume of 500 µl to induce antibody production. After 1 week and 2 weeks, an emulsion mixed with each Freund's complete adjuvant (Sigma, USA) and the antigen was additionally injected into the peritoneal cavity of the mouse.

[0112] 1-2. Confirmation and screening of antibody-producing cells

[0113]Blood was collected from the eyeball of the mouse immunized by the...

Embodiment 2

[0120] Example 2. Determination of Stem Cell Factor Neutralizing Ability of Dual Targeting Antibodies

[0121] After 300 μl of Matrigel (Corning, USA) was dispensed into a 12-well plate, human umbilical vein endothelial cells (HUVEC, Human Umbilical Vein Endothelial Cells) were mixed with stem cell factor (50 ng / ml) or stem cell factor (50 ng / ml) + anti-stem cell factor antibody (10 μg / ml) were mixed and injected into Matrigel, and the tube formation of human umbilical vein endothelial cells was observed in vitro (n=10). show the result in figure 2 .

[0122] Such as figure 2 As shown, it was confirmed that the 3C3 and 3C4 antibodies effectively inhibited the tube formation of human umbilical vein endothelial cells induced by stem cell factor among the 9 monoclonal antibodies. From the above results, it can be confirmed that the 3C3 and 3C4 antibodies of the present invention can be used to prevent or treat angiogenesis-related diseases by inhibiting angiogenesis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a dual-targeting antibody targeting stem cell factor (SCF) and galectin-1 and a composition for preventing or treating angiogenesis-related diseases comprising the same. The present invention provides a dual-targeting antibody derived from a human monoclonal antibody which can effectively inhibit angiogenesis by simultaneously neutralizing SCF and galectin-1 involved in angiogenesis, and a pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising the antibody. The dual-targeting antibody according to the present invention can effectively prevent or treat angiogenesis-related diseases by simultaneously neutralizing two targets involved in angiogenesis wherein the angiogenesis-related diseases cause hemorrhaging by blood vessels changing due to abnormal angiogenesis and thus increasing the permeability thereof.

Description

technical field [0001] The present invention relates to a dual targeting antibody targeting stem cell factor (SCF, Stem Cell Factor) and galectin-1 (Galectin-1) and a composition containing the same for preventing or treating diseases related to angiogenesis. Background technique [0002] Stem cell factor is known to be a factor deeply involved in the differentiation of blood cells, sperm, and melanocytes. It is known that it is mainly produced in fibroblasts and endothelial cells, and promotes angiogenesis by increasing expression and secretion under hypoxia. In addition, Galectin-1 is known as a factor that induces angiogenesis by binding to a receptor of vascular endothelial growth factor (VEGF, Vascular Endothelial Growth Factor), a representative protein that regulates angiogenesis, by being secreted in a hypoxic state. , even when vascular endothelial growth factor is inhibited, blood vessels are induced by galectin-1 as a new ligand. [0003] Angiogenesis is the gen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24G01N33/68
CPCC07K16/24C07K16/2851C07K2317/76C07K2317/24C07K2317/92C07K2317/33G01N2800/7014G01N33/6893G01N33/6863G01N2333/52G01N2800/16A61K2039/505C07K2317/565
Inventor 朴商奎
Owner NOVELTY NOBILITY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com